89bio, Inc. (ETNB)
ETNB Stock Price Chart
Explore 89bio, Inc. interactive price chart. Choose custom timeframes to analyze ETNB price movements and trends.
ETNB Company Profile
Discover essential business fundamentals and corporate details for 89bio, Inc. (ETNB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2019
Employees
93.00
Website
https://www.89bio.comCEO
Rohan Palekar
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Financial Timeline
Browse a chronological timeline of 89bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.50.
Earnings released on 7 Aug 2025
EPS came in at -$0.71 falling short of the estimated -$0.49 by -44.90%.
Earnings released on 1 May 2025
EPS came in at -$0.49 surpassing the estimated -$0.50 by +2.00%.
Earnings released on 27 Feb 2025
EPS came in at -$1.02 falling short of the estimated -$0.60 by -70.00%, while revenue for the quarter reached $21.00K .
Earnings released on 7 Nov 2024
EPS came in at -$1.39 falling short of the estimated -$0.54 by -157.41%.
Earnings released on 5 Aug 2024
EPS came in at -$0.48 surpassing the estimated -$0.56 by +14.29%.
Earnings released on 9 May 2024
EPS came in at -$0.54 falling short of the estimated -$0.48 by -12.50%.
Earnings released on 29 Feb 2024
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $234.00K .
Earnings released on 8 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.50 by +10.00%.
Earnings released on 9 Aug 2023
EPS came in at -$0.52 falling short of the estimated -$0.41 by -26.83%.
Earnings released on 4 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.56 by +3.57%.
Earnings released on 10 Mar 2023
EPS came in at -$0.48 surpassing the estimated -$0.63 by +23.81%.
Earnings released on 10 Nov 2022
EPS came in at -$0.57 surpassing the estimated -$0.89 by +35.96%.
Earnings released on 11 Aug 2022
EPS came in at -$1.23 falling short of the estimated -$1.04 by -18.27%.
Earnings released on 11 May 2022
EPS came in at -$1.26 surpassing the estimated -$1.38 by +8.70%.
Earnings released on 24 Mar 2022
EPS came in at -$1.30 surpassing the estimated -$1.51 by +13.91%.
Earnings released on 11 Nov 2021
EPS came in at -$1.41 falling short of the estimated -$1.07 by -31.78%.
Earnings released on 12 Aug 2021
EPS came in at -$1.03 falling short of the estimated -$0.86 by -19.77%.
Earnings released on 12 May 2021
EPS came in at -$0.74 falling short of the estimated -$0.67 by -10.45%.
Earnings released on 24 Mar 2021
EPS came in at -$0.63 surpassing the estimated -$0.90 by +30.00%.
Earnings released on 10 Nov 2020
EPS came in at -$0.86 surpassing the estimated -$0.89 by +3.37%.
ETNB Stock Performance
Access detailed ETNB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.